Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AZTR | EFFECT | bearish | 7/10 | The SEC declared effective Azitra's S-1 registration statement (File No. 333-296125) on June 2, 2026, covering the resal | Jun 3, 2026 |
| CTXR | EFFECT | bearish | 6/10 | The SEC declared effective Citius Pharmaceuticals' S-3 shelf registration (File No. 333-296195) on June 2, 2026. This en | Jun 3, 2026 |
| MNKD | PRESS-RELEASE | neutral | 5/10 | MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first pa | Jun 3, 2026 |
| APLMW | EFFECT | bearish | 5/10 | Apollomics Inc.'s F-3 shelf registration (File No. 333-294154) was declared effective by the SEC on June 2, 2026. This a | Jun 3, 2026 |
| MLYS | 8-K | mixed | 7/10 | Mineralys Therapeutics entered into a $200M one-time cash payment to Tanabe Pharma to buy out all future royalty obligat | Jun 3, 2026 |
| IVEVF | 6-K | bullish | 7/10 | Inventiva S.A. filed a 6-K attaching a Subscription Agreement with funds managed by BlackRock and Claret Capital Partner | Jun 3, 2026 |
| BCTXZ | 8-K | bearish | 6/10 | BriaCell Therapeutics Corp. closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, raising gross | Jun 3, 2026 |
| MLYS | PRESS-RELEASE | bullish | 7/10 | Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secur | Jun 3, 2026 |
| MIRM | CLUSTER | neutral | 2/10 | Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in open-market sales on | Jun 2, 2026 |
| OKYO | 3 | neutral | 2/10 | Bernard Denoyer filed a Form 3 initial statement of beneficial ownership with OKYO Pharma Ltd, disclosing options to acq | Jun 2, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Three Neurocrine executives (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer) sold a total of $2.73M in open- | Jun 2, 2026 |
| NBIX | CLUSTER | neutral | 2/10 | Three NBIX insiders, including the Chief Scientific Officer, sold a combined $2.67M in open-market shares over a 4-day w | Jun 2, 2026 |
| VIR | CLUSTER | neutral | 2/10 | Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, following a wave of non-cas | Jun 2, 2026 |
| NRXPW | 424B5 | bearish | 6/10 | NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment common stock offering | Jun 2, 2026 |
| BTMD | 8-K | neutral | 4/10 | CEO Bret Christensen resigned for family/personal reasons effective June 8, 2026, and will remain on the board. CFO/Chie | Jun 2, 2026 |
| HRTX | 8-K | bearish | 7/10 | The U.S. District Court for the District of Delaware held that the asserted claims of Heron's CINVANTI patents (U.S. Pat | Jun 2, 2026 |
| SCLXW | S-3 | bearish | 6/10 | Scilex Holding Company filed an S-3 shelf registration to register up to 2,083,067 primary shares issuable upon exercise | Jun 2, 2026 |
| STTK | 8-K | neutral | 3/10 | Shattuck Labs held its 2026 Annual Meeting on May 28, 2026. Stockholders approved an amendment and restatement of the 20 | Jun 2, 2026 |
| CUE | 8-K | neutral | 4/10 | Cue Biopharma announced the immediate resignation of four board members (Jill Broadfoot, Peter Kiener, Frank Morich, Pat | Jun 2, 2026 |
| EVMN | 144 | neutral | 3/10 | Director David E. Cohen filed a Form 144 notice of intent to sell 9,258 shares of Evommune (EVMN) common stock, with an | Jun 2, 2026 |
| ASND | CLUSTER | bullish | 4/10 | CFO Scott Thomas and Director Jean-Jacques Bienaimé made open-market purchases totaling $67K over a 5-day window. While | Jun 2, 2026 |
| HOTH | 8-K | neutral | 2/10 | Rocket One Inc. announced the appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Tech | Jun 2, 2026 |
| CTKB | 8-K | neutral | 3/10 | Cytek Biosciences disclosed the resignation of Philippe Busque, Ph.D., Senior Vice President of Global Sales and Service | Jun 2, 2026 |
| JAGX | 8-K | bearish | 6/10 | Jaguar Health entered into two exchange agreements with Streeterville Capital, converting 7.92 shares of Series Q Prefer | Jun 2, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Four insiders at Twist Bioscience sold a total of $1.31M in open-market sales over a 7-day window, including the CEO (vi | Jun 2, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Two Corcept Therapeutics insiders sold a combined $3.89M in open-market sales on May 27, 2026, with CEO Belanoff also gi | Jun 2, 2026 |
| GLUE | CLUSTER | neutral | 3/10 | Three top executives at Monte Rosa Therapeutics (CEO, CSO, COO) sold a combined $260K in open-market sales over a 7-day | Jun 2, 2026 |
| PCVX | PRESS-RELEASE | neutral | 4/10 | Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Gr | Jun 2, 2026 |
| GELS | 6-K | bearish | 7/10 | Gelteq is holding a special shareholder meeting on June 19, 2026, to seek approval under Nasdaq Listing Rule 5635(d) for | Jun 2, 2026 |
| CMMB | 6-K | neutral | 2/10 | Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance | Jun 2, 2026 |